IMIQUIMOD
Imiquimod is an immune-response modifier that stimulates interferon production to treat skin lesions such as warts and superficial cancers. Side effects include redness, swelling, irritation, and flu-like symptoms.
About MedicaPharma
MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.
Network of over +400 GMP API producers
Let us handle your sourcing / supply activities. Highly experienced in sourcing specialty raw pharmaceutical ingredients from niche GMP manufacturers around the world.
Why Choose MedicaPharma
Niche API specialist - Pro-active supply partner - High service level - Global network - Logistics according to GDP regulations
Product Description
Mechanism of Action
IMIQUIMOD (ID 26415) exhibits a multi-dimensional biochemical activity profile that affects cellular regulation at enzyme, receptor, and transcriptional levels. Its molecular interactions can alter phosphorylation cycles, modulate ionic homeostasis, influence mitochondrial respiration, and adjust redox-signaling pathways. Structural properties suggest specific affinity for regulatory proteins, enabling modulation of metabolic flux and cellular response thresholds.
Benefits and Advantages
This compound is suited for high-resolution mechanistic research, multi‑omics integration studies, receptor-binding experiments, enzyme-pathway mapping, and advanced pharmacodynamic modelling. It supports ROS-regulation assays, signalling-cascade analysis, cytoskeletal‑dynamics research, and metabolic adaptation models. Due to predictable biochemical behaviour, it is often used as a comparative reference in pathway‑perturbation studies.
- Useful in mechanistic pharmacology and biochemical modelling
- Applicable in oxidative-stress, mitochondrial-function and signalling studies
- Reliable for transcriptional and proteomic profiling
- Supports SAR (structure–activity relationship) investigations
Side Effects and Risks
Potential risks include mitochondrial overload, ROS imbalance, inadvertent receptor cross‑talk, disruption of ion-channel dynamics, and dose-dependent cytotoxicity. High exposure may trigger apoptosis, autophagy, or cellular stress-response activation. Controlled handling conditions and biosafety protocols are required for laboratory use.
Datasheet
| Molecular Formula | C14H16N4 |
|---|---|
| Molecular Weight | 240.30 g/mol |
| CAS Number | 99011-02-6 |
| Storage Condition | Imiquimod topical cream should be stored at 4-25 °C; freezing should be avoided. |
| Solubility | Poorly soluble |
| Purity | Purity information is available upon request (COA). |
| Synonym | IMIQUIMOD; 99011-02-6; Aldara; Zyclara; 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine |
| IUPAC/Chemical Name | 1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine |
| InChl Key | DOUYETYNHWVLEO-UHFFFAOYSA-N |
| InChl Code | InChI=1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17) |
| References |
3D Conformer.
(Click, turn or enlarge)
Download our GMP API Product List.
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.


